Evidence map›Paper›PMID 40478351›Full record

ReviewCurrent gastroenterology reports2025

Evolving Role of GLP-1 Therapies in Liver Disease.

Mark Lindsay, Gretchen Arndt, Amanda Wieland, Thomas Jensen

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current gastroenterology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mark LindsayDepartment of Medicine, Division of Endocrinology, Metabolism, and Diabetes, University of Colorado Medicine, Aurora, CO, US.
Gretchen ArndtDepartment of Medicine, Division of Endocrinology, Metabolism, and Diabetes, University of Colorado Medicine, Aurora, CO, US.
Amanda WielandDepartment of Medicine, Division of Hepatology, University of Colorado Medicine, Aurora, CO, US.
Thomas JensenDepartment of Medicine, Division of Endocrinology, Metabolism, and Diabetes, University of Colorado Medicine, Aurora, CO, US. Thomas.jensen@cuanschutz.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewMetabolic dysfunction-associated steatotic liver disease (MASLD) has become the leading cause of chronic liver disease. This risk paralleled the rise in obesity rates, making MASLD a consequence of the Metabolic Syndrome (MetS). Until recently, clinicians have had limited pharmaceutical options in management this disorder. Glucagon-like Peptide 1 Receptor Agonist (GLP-1 RA) treatments have emerged as potential agents for noted benefits in many aspects related to the pathology and progression of MASLD. RECENT

findingsNumerous trials including a recent Phase 3 trial utilizing GLP-1 RA based therapies have shown benefits for improvement in MASLD including MASH and fibrosis. Molecules that also act upon the glucose-dependent insulinotropic polypeptide (GIP) and/or glucagon have shown potential synergistic benefits in reversing inflammation and fibrosis. In summary, GLP-1 RA based therapies are being rigorously studied in management of MASLD in particular more advanced stages and likely will become foundational therapies in the future.

Indexed as

Fatty LiverGlucagon-Like Peptide 1Glucagon-Like Peptide-1 Receptor AgonistsHumansIncretinsLiver CirrhosisMetabolic SyndromeNon-alcoholic Fatty Liver DiseaseGlucagon-Like Peptide 1Glucagon-Like Peptide-1 Receptor AgonistsIncretinsCirrhosisGLP-1MASHMASLD

Identifiers

PMID40478351

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.